CN105658222A - 游离碱晶体 - Google Patents

游离碱晶体 Download PDF

Info

Publication number
CN105658222A
CN105658222A CN201480046150.4A CN201480046150A CN105658222A CN 105658222 A CN105658222 A CN 105658222A CN 201480046150 A CN201480046150 A CN 201480046150A CN 105658222 A CN105658222 A CN 105658222A
Authority
CN
China
Prior art keywords
methyl
crystal
phenyl
crystals
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480046150.4A
Other languages
English (en)
Chinese (zh)
Inventor
安倍隆
G·巴克顿
R·戴维斯
M·霍珀
P·李
丸山秀明
高须正浩
L·P·文诺格勒
山本裕平
山下弘典
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Priority to CN202110144523.3A priority Critical patent/CN112851683A/zh
Priority to CN201910526464.9A priority patent/CN110498800A/zh
Publication of CN105658222A publication Critical patent/CN105658222A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201480046150.4A 2013-06-21 2014-06-20 游离碱晶体 Pending CN105658222A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110144523.3A CN112851683A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN201910526464.9A CN110498800A (zh) 2013-06-21 2014-06-20 游离碱晶体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838105P 2013-06-21 2013-06-21
US61/838,105 2013-06-21
US201361919424P 2013-12-20 2013-12-20
US61/919,424 2013-12-20
PCT/US2014/043422 WO2014205354A2 (en) 2013-06-21 2014-06-20 Free base crystals

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201910526464.9A Division CN110498800A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN202110144523.3A Division CN112851683A (zh) 2013-06-21 2014-06-20 游离碱晶体

Publications (1)

Publication Number Publication Date
CN105658222A true CN105658222A (zh) 2016-06-08

Family

ID=52105535

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201480046150.4A Pending CN105658222A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN201910526464.9A Pending CN110498800A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN202110144523.3A Pending CN112851683A (zh) 2013-06-21 2014-06-20 游离碱晶体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201910526464.9A Pending CN110498800A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN202110144523.3A Pending CN112851683A (zh) 2013-06-21 2014-06-20 游离碱晶体

Country Status (13)

Country Link
US (1) US9630971B2 (enExample)
EP (2) EP3010509B1 (enExample)
JP (2) JP6865036B2 (enExample)
KR (2) KR102430126B1 (enExample)
CN (3) CN105658222A (enExample)
AU (1) AU2014284224B2 (enExample)
BR (1) BR112015032132B1 (enExample)
CA (1) CA2916393C (enExample)
ES (1) ES2894770T3 (enExample)
IL (2) IL267331B2 (enExample)
MX (2) MX2015017972A (enExample)
RU (1) RU2675851C2 (enExample)
WO (1) WO2014205354A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
AR091507A1 (es) * 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
EP3010509B1 (en) 2013-06-21 2021-07-28 Intra-Cellular Therapies, Inc. Free base crystals
US12410175B2 (en) 2019-09-03 2025-09-09 Intra-Cellular Therapies, Inc. Compounds
US12435093B2 (en) 2020-05-06 2025-10-07 Intra-Cellular Therapies, Inc. Free base crystals
WO2022026417A1 (en) * 2020-07-26 2022-02-03 Intra-Cellular Therapies, Inc. Novel uses
JP2024531548A (ja) * 2021-09-03 2024-08-29 イントラ－セルラー・セラピーズ・インコーポレイテッド 共結晶
WO2023147484A1 (en) * 2022-01-27 2023-08-03 Intra-Cellular Therapies, Inc. Novel compositions
WO2023147603A2 (en) * 2022-01-31 2023-08-03 Intra-Cellular Therapies, Inc. Salt crystals
WO2023233410A1 (en) * 2022-06-02 2023-12-07 Biosight Ltd. Crystalline form of aspacytarabine intermediate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970444A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
US5471001A (en) * 1994-12-15 1995-11-28 E. I. Du Pont De Nemours And Company Crystallization of adipic acid
GB9624615D0 (en) * 1996-11-26 1997-01-15 Zeneca Ltd Chrystallisation process
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
ATE496028T1 (de) * 2002-02-08 2011-02-15 Ono Pharmaceutical Co Piperidinderivatverbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
EP1613747A1 (en) 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
CN100457108C (zh) * 2003-09-02 2009-02-04 默克公司 一种二肽基肽酶iv抑制剂的磷酸盐新晶体
CN101031548B (zh) * 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
PE20110922A1 (es) * 2008-12-06 2012-01-22 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US8858911B2 (en) 2009-10-08 2014-10-14 Intra-Cellular Therapies, Inc. Phosphodiesterase 1-targeting tracers and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
AR091507A1 (es) * 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
EP3010509B1 (en) 2013-06-21 2021-07-28 Intra-Cellular Therapies, Inc. Free base crystals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970444A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物

Also Published As

Publication number Publication date
CN110498800A (zh) 2019-11-26
EP3010509A2 (en) 2016-04-27
EP3010509A4 (en) 2016-11-23
KR102430126B1 (ko) 2022-08-05
RU2016101630A (ru) 2017-07-26
WO2014205354A3 (en) 2015-05-28
AU2014284224B2 (en) 2019-08-01
BR112015032132A2 (pt) 2017-07-25
KR20160040522A (ko) 2016-04-14
EP3702358A1 (en) 2020-09-02
JP2019189618A (ja) 2019-10-31
JP6865036B2 (ja) 2021-04-28
MX2020001628A (es) 2020-07-13
CA2916393C (en) 2022-03-22
IL267331B2 (en) 2024-12-01
CA2916393A1 (en) 2014-12-24
CN112851683A (zh) 2021-05-28
ES2894770T3 (es) 2022-02-15
US9630971B2 (en) 2017-04-25
WO2014205354A2 (en) 2014-12-24
MX2015017972A (es) 2016-10-28
RU2675851C2 (ru) 2018-12-25
IL267331B1 (en) 2024-08-01
RU2016101630A3 (enExample) 2018-03-21
IL243269A0 (en) 2016-02-29
AU2014284224A1 (en) 2016-02-11
KR20210122890A (ko) 2021-10-12
IL267331A (en) 2019-08-29
IL243269B (en) 2019-06-30
US20160145261A1 (en) 2016-05-26
HK1223848A1 (zh) 2017-08-11
EP3010509B1 (en) 2021-07-28
BR112015032132B1 (pt) 2022-03-15
JP2016523258A (ja) 2016-08-08

Similar Documents

Publication Publication Date Title
JP6865036B2 (ja) 遊離塩基結晶
CN104602695B (zh) 盐晶体
CN108699063A (zh) 一种芦可替尼的合成工艺
CN105073752B (zh) 制备三环化合物的方法以及可通过所述制备方法制备的三环化合物
US12435093B2 (en) Free base crystals
HK40036801A (en) Process for preparing salts of a known pde1 inhibitor
CN117105931A (zh) 一种制备吡啶并嘧啶类化合物的方法及其中间体
JP2025505577A (ja) （６ａ，１２ａ）－１７－アミノ－１２－メチル－６，１５－ビス（トリフルオロメチル）－１３，１９－ジオキサ－３，４，１８－トリアザトリシクロ［１２．３．１．１２，５］ノナデカ－１（１８），２，４，１４，１６－ペンタエン－６－オールの調製方法及び結晶形態
EP2847195A1 (en) Form 2 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
HK1223848B (en) Free base crystals
CN105940003A (zh) 替格瑞洛合成中间物的制备方法和新颖结晶形式
CN102898397B (zh) (4aR,10bR)-3,4,4a,5,6,10b-六氢-2H-萘并[1,2-b][1,4]噁嗪-9-醇类物质及其盐酸盐合成方法
HK40090878A (en) Process for the preparation of 1-methyl-6-[6-r2-5-methyl-8-(methylamino)-4-[ (3as,6as)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-1-yl]-9h-pyrido[2,3-b]indol-3-yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride
HK40125773A (en) Iap antagonist compounds and intermediates and methods for synthesizing the same
HK1247191A1 (en) Salt crystals
WO2013170241A1 (en) Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolol[4,3b]pyridazine
CN102439010A (zh) 稠合三环磺酰胺的制备方法
HK1223613B (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160608

RJ01 Rejection of invention patent application after publication